A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis. - Spelman L; Rubel D; Brnabic A; Burkhardt N; Riedl E; Foley P (The Journal of dermatological treatment, 2022)